Amikacin News and Research

RSS
Understanding the rise in NTM infections

Understanding the rise in NTM infections

Study finds high rates of drug resistance to urinary tract infections in Bangladesh

Study finds high rates of drug resistance to urinary tract infections in Bangladesh

New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

Novel rapid diagnostic test and shorter treatment with better outcomes may benefit MDR-TB patients

Novel rapid diagnostic test and shorter treatment with better outcomes may benefit MDR-TB patients

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of TB

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of TB

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

New TB-Profiler tool to find appropriate drugs for TB patients may improve likelihood of cure

New TB-Profiler tool to find appropriate drugs for TB patients may improve likelihood of cure

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Specific therapy may cut pneumonia mortality in HIV babies

Specific therapy may cut pneumonia mortality in HIV babies

New approach can design antibiotics that kill even 'superbugs'

New approach can design antibiotics that kill even 'superbugs'

Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Insmed fourth quarter revenues increase to $1.4 million

Insmed fourth quarter revenues increase to $1.4 million

Insmed third quarter revenues decrease to $0.4 million

Insmed third quarter revenues decrease to $0.4 million